These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22528765)

  • 21. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.
    Biver E; Calmy A; Aubry-Rozier B; Birkhäuser M; Bischoff-Ferrari HA; Ferrari S; Frey D; Kressig RW; Lamy O; Lippuner K; Suhm N; Meier C
    Osteoporos Int; 2019 May; 30(5):1125-1135. PubMed ID: 30603840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
    Bruera D; Luna N; David DO; Bergoglio LM; Zamudio J
    AIDS; 2003 Sep; 17(13):1917-23. PubMed ID: 12960824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.
    Ofotokun I; Titanji K; Lahiri CD; Vunnava A; Foster A; Sanford SE; Sheth AN; Lennox JL; Knezevic A; Ward L; Easley KA; Powers P; Weitzmann MN
    Clin Infect Dis; 2016 Sep; 63(5):663-671. PubMed ID: 27193748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.
    Cervero M; Torres R; Agud JL; Alcázar V; Jusdado JJ; García-Lacalle C; Moreno S
    PLoS One; 2018; 13(4):e0196201. PubMed ID: 29709013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection.
    Brown TT
    Top Antivir Med; 2013; 21(3):115-8. PubMed ID: 23981599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone disease in HIV infection: a practical review and recommendations for HIV care providers.
    McComsey GA; Tebas P; Shane E; Yin MT; Overton ET; Huang JS; Aldrovandi GM; Cardoso SW; Santana JL; Brown TT
    Clin Infect Dis; 2010 Oct; 51(8):937-46. PubMed ID: 20839968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients.
    Negredo E; Warriner AH
    Curr Opin HIV AIDS; 2016 May; 11(3):351-7. PubMed ID: 26890207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.
    Pinzone MR; Moreno S; Cacopardo B; Nunnari G
    AIDS Rev; 2014; 16(4):213-22. PubMed ID: 25300622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spontaneous supracondylar femoral fracture in an HIV patient in lotus position.
    Pinto Neto LF; Eis SR; Miranda AE
    J Clin Densitom; 2011; 14(1):74-6. PubMed ID: 21295744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: A meta-analysis.
    Yao L; Wang H; Dong W; Liu Z; Mao H
    Medicine (Baltimore); 2017 Jan; 96(3):e5861. PubMed ID: 28099343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporosis and HIV.
    O'Connor MB
    Ir J Med Sci; 2013 Dec; 182(4):747-8. PubMed ID: 23588816
    [No Abstract]   [Full Text] [Related]  

  • 33. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mass in HIV-infected patients: focus on the role of therapy and sex.
    Vescini F; Borderi M; Buffa A; Sinicropi G; Tampellini L; Chiodo F; Caudarella R
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):405-7. PubMed ID: 12843753
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
    HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
    Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
    Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age.
    Jacobson DL; Lindsey JC; Gordon C; Hazra R; Spiegel H; Ferreira F; Amaral FR; Pagano-Therrien J; Gaur A; George K; Benson J; Siberry GK
    Clin Infect Dis; 2020 Aug; 71(5):1281-1288. PubMed ID: 31573608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone Density and Fractures in HIV-infected Postmenopausal Women: A Systematic Review.
    Cortés YI; Yin MT; Reame NK
    J Assoc Nurses AIDS Care; 2015; 26(4):387-98. PubMed ID: 26066693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.